VKTX Shares Fall 6% as Investors Await Obesity Trial Results
Viking Therapeutics shares were down 6% Monday after roughly 6% gains Friday, as investors reassessed clinical data amid unconfirmed takeover speculation. Investors are also awaiting topline results from a key obesity trial.
Viking Therapeutics (VKTX) shares were on track to give back Friday’s roughly 6% gains on Monday, with investors reassessing the biotech’s latest clinical data after a rally driven by unconfirmed takeover speculation.VKTX stock was trading 6% lower at the time of writing.Friday’s Takeover-Driven Sp…